Viagra Now Available "At Low Price" In Italy
Italy's Health Minister Rosy Bindi has said that the average cost ofPfizer's impotence drug Viagra (sildenafil), which has just gone on sale in Italy's pharmacies, will be among the lowest in Europe. She also warned that improper use of Viagra, dubbed il farmaco d'amore by the press, could have fatal effects.
The drug will be sold in 25mg, 50mg and 100mg dosages, at an average price per pill of 20,000 lire ($12.22). The Ministry says international price variations are due to value-added tax. The drug is listed in category C; patients will pay the full cost.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze